Brind.
  1. A company has entered into a non-clinical evaluation agreement with NIAID, partnering with AFRRI on protocol design that meets FDA Animal Rule criteria.

NIAID Funds AFRRI Study on Valion Bio's Entolimod Efficacy

3 reports, 1 independent Updated Fri 00:00
No new developments lately Reached 3 outlets in its first 24 hours
Reports
3
Developments
1
Repetition
67%

New informationRepeats or wire copies

AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Valion Bio, Inc. announced that the Armed Forces Radiobiology Research Institute will evaluate the therapeutic efficacy of its drug, Entolimod. The study assesses whether treatment administered after radiation exposure improves survival in a model designed to measure gastrointestinal acute radiation syndrome. This therapeutic study is fully funded by the National Institute of Allergy and Infectious Diseases. Top-line results are expected in early December.

From californiatelegraph.com

Why it matters

Some supportBrind's analysis of the reports

The decision to advance the program to therapeutic efficacy testing marks a clear next milestone for Valion Bio, following positive safety findings. This advancement could potentially strengthen Valion Bio's competitive position and commercial opportunities.

Valion Bio, Inc. had previously entered into a non-clinical evaluation agreement with the National Institute of Allergy and Infectious Diseases, partnering with the Armed Forces Radiobiology Research Institute on protocol design.

From californiatelegraph.com

Who's involved

Keep exploring

Part of

A company has entered into a non-clinical evaluation agreement with NIAID, partnering with AFRRI on protocol design that meets FDA Animal Rule criteria. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
2 more outlets ran the same wire story